1541 — ImmuneOnco Biopharmaceuticals (Shanghai) Share News
0.000.00%
Last trade - 00:00- HK$1.57bn
- HK$660.22m
- CNY154.29m
Brief: ImmuneOnCo Biopharmaceuticals (Shanghai) To Repurchase H Shares In Open Market
Brief: Immuneonco Biopharmaceuticals (Shanghai)Subscribes For Hk$212 Million Wealth Management Product
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives Approval From NMPA China For Investigational New Drug Application Of IMM0306S
Brief: ImmuneOnco Biopharmaceuticals Shanghai Receives NMPA Approval For Clinical Trial Of IMM01 (Timdarpacept)
Brief: Immuneonco Biopharmaceuticals Shanghai Says Immuneonco To Regain Global Rights- To IMM2510, IMM27M
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Says CEO Purchases 50,000 H Shares At Average Price Of HK$6.6258 Each
Brief: ImmuneOnco Biopharmaceuticals Shanghai's Chairman Purchases 50,000 H Shares
China's ImmuneOnco drops most in 6 months on discounted share sale
Brief: Immuneonco Biopharmaceuticals Shanghai Says Placing Of Total 24.2 MLN New H Shares At HK$14.50 Per Share
Brief: Immuneonco Biopharmaceuticals Shanghai Submits Phase III Trial Application For Imm0306
Brief: Immuneonco Biopharmaceuticals Shanghai Says Clearance Of Ind Application For Imm2510/Axn-2510 By FDA
Brief: Immuneonco Biopharmaceuticals Shanghai Inc Recives Approval By NMPA For Clinical Trial Of Imc-003/Imm72
Brief: Immuneonco Biopharmaceuticals Shanghai Gives Notice To Haitong ASM To Redeem HK$200 Million Product
Advisory: Alerts incorrectly tagged to T Rowe Price Large-Cap Value Fund withdrawn
Brief: Immuneonco Biopharmaceuticals Shanghai Says NMPA Accepted Application For Clinical Trial Of Imc-003/Imm72
Brief: Immuneonco Biopharmaceuticals Shanghai Says CEO Purchased 150,000 H Shares Of Co
Brief: Immuneonco Biopharmaceuticals Shanghai Says Revenue Was RMB74.1 Million For Year
Brief: Immuneonco Biopharmaceuticals Shanghai Gets Approval For Clinical Trial Of IMM01 (Timdarpacept)